Best Infectious Diseases Companies in Texas, United States
The 45 best Infectious Diseases companies in Texas, United States in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: AlloVir.
Our analysis of 50 Infectious Diseases companies
$7.1b in tracked funding; 59% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Infectious Diseases companies in Texas
| # | Company | Disclosed funding | Last round | Employees | Founder | Stage | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|
| 1 | AlloVir Developer of T-cell therapies to treat infectious diseases | $151M | 87 mo ago | 97 | David Hallal Co-Founder | Public | 8 patents Ex vivo expansion and manufacturing of multivirus-specific T‑cell therapies for transplant immunotherapy | — |
| 2 | Xenex Provider of disinfection robots for multiple healthcare purposes | $94M | 90 mo ago | 79 | — | Series D | — | — |
| 3 | Nano Provider of vaccine development and management devices for researchers | $90M | 65 mo ago | 27 | Steve Papermaster CEO & Chairman | Series C | 243 patents Nanomaterial-based conductive inks, transparent electrodes, and optoelectronic coatings | — |
| 4 | Pattern Bioscience Provider of multiple diagnostics platforms for infectious diseases 60Patents top 20%Funding top 25%Innovation top 26%Moat top 32% All 10 signals ▾Patentstop 20% Fundingtop 25% Innovationtop 26% Moattop 32% Growthtop 37% Talenttop 38% Techbottom 46% Marketbottom 38% Globalbottom 38% Newsbottom 22% Patents: 58 patents matched (strict assignee match) · 42 filings since 2022 vs 16 in 2017-21 Funding: Raised $68.0M across 7 rounds · 7 rounds over 7 yrs (1.0/yr) rank vs industry peers · Fliar Intelligence Index 60/100 | $68M | 12 mo ago | 58 58 → 77 (+33%) | Ross Johnson Co-Founder | Series C | 58 patents Microfluidic single‑cell diagnostic platforms and sample‑handling technologies for cellular phenotyping | 1 award |
| 5 | Vaxxinity Developer of vaccines for neurological disorders and infectious diseases | $27M | 64 mo ago | 92 | — | Public | 34 patents Patents concentrated in health & consumer products | — |
| 6 | LabNow Domain registration verification service ensuring domain name resolution and preventing deletion | $22M | 195 mo ago | — | Brandon Phillips Managing Partner & CEO | Deadpooled | 7 patents Automated white blood cell counting and analysis for clinical diagnostic laboratories | — |
| 7 | Nuclein Developer of handheld PCR device for the detection of infectious disease | $20M | 13 mo ago | 27 | Alan Blake Chief Executive Officer | Series B | 24 patents Patents concentrated in transport & manufacturing processes | — |
| 8 | Asylia Therapeutics Developer of medicines for cancer, autoimmune, and infectious diseases | $14M | 16 mo ago | 4 | Richard Jones Co-Founder | Series A | — | — |
| 9 | Phoenix Biotechnology Develops plant based therapies for treatment of cancer | $13M | 72 mo ago | 7 | — | Series B | 207 patents Developing therapeutic compounds for viral, cancer, and skin disease treatments. | — |
| 10 | Memgen Developer of immunotherapies to treat cancer | $12M | 20 mo ago | 9 | — | Series A | 72 patents Oncolytic viral platforms and immune‑modulating vaccine adjuvants for cancer and infectious disease | — |
| 11 | MaxWell Biosciences Engineering personalized human blood to optimize cognitive performance and reverse Alzheimer's disease | $11M | 12 mo ago | 13 | — | Series A | 55 patents Antimicrobial peptoid therapeutics and anti‑biofilm coating technologies for wound and device protection | — |
| 12 | Curative Provider of self collecting COVID-19 testing centers listing platform 48Tech top 20%Innovation top 31%Patents top 33%News top 39% All 11 signals ▾Techtop 20% Innovationtop 31% Patentstop 33% Newstop 39% Fundingtop 42% Growthtop 42% Producttop 49% Moatbottom 44% Marketbottom 43% Globalbottom 33% Fin. healthbottom 14% Tech: 40 technologies across 6/8 capability areas · Cloud: Amazon Web Services, Cloudflare Innovation: 10 patents (top 47% of patent-holders) · 8 filings since 2022 vs 0 in 2017-21 rank vs industry peers · Fliar Intelligence Index 48/100 | $10M | 9 mo ago | 2,251 | — | Series B | 10 patents Molecular diagnostic sample collection, nucleic acid purification, and infection profiling technologies. | 1 award |
| 13 | Paratus Diagnostics Point-of-care diagnostic systems for infectious diseases | $8M | 92 mo ago | 5 | John Carrano Founder & CEO | Series A | 27 patents Microfluidic fluid metering and timing for point‑of‑care diagnostic cartridges, including nucleic‑acid extraction. | — |
| 14 | EnvantageDX In-vitro diagnostics for rapid ear, nose, and throat illness detection | $7M | 67 mo ago | 6 | Joseph Skraba President & CEO | Series A | — | — |
| 15 | Bacterial Barcodes Provides solutions to track hospital-acquired infections (HAI) and for environmental control for product… | $6M | 282 mo ago | — | Mimy Healy Ex-CEO and President | Acqui-Hired | 4 patents Bacterial strain identification using repetitive DNA barcode PCR amplification | — |
| 16 | Sano Chemicals Developing novel solutions for drug-resistant bacterial and fungal infections | $4M | 25 mo ago | 6 | James Smith Co-Founder & CEO | Seed | — | — |
| 17 | Angstrom Provider of high-frequency COVID-19 and respiratory pathogen testing platform | $3M | 62 mo ago | 7 | — | Series A | 245 patents MEMS micromirror optical imaging, stabilization, and high‑resolution toner printing technologies | — |
| 18 | Ayuvis Developing immunotherapies to prevent and treat life-threatening diseases | $2M | 16 mo ago | 10 | Suchismita Acharya Founder & CEO | Seed | — | — |
| 19 | E-Mist Innovations Electrostatic System for Infection Control | $1M | 111 mo ago | 23 | George Robertson CEO | Seed | — | — |
| 20 | DxUpClose Point-of-care bacterial diagnostics | $1M | 168 mo ago | 1 | Cyndi Nickel Founder & CEO | Series A | 8 patents Rapid microbial identification and antimicrobial susceptibility testing devices | — |
| 21 | Magnolia Diagnostics Diagnostic lab providing fast, accurate results for providers and patients | $938K | 103 mo ago | 21 | Kelly Bains Co-Founder | Seed | — | — |
| 22 | Avsana Labs Developer of point-of-care diagnostics for respiratory syncytial virus | $596K | 49 mo ago | — | Zhenpeng Qin Co-Founder | Funding Raised | — | — |
| 23 | Aperture Bio Developer of in-vitro diagnostics for drug-resistant bacterial infections | $100K | 34 mo ago | — | Kevin Kuykendall CEO | Seed | — | — |
Top 12 Infectious Diseases companies in Texas
#1
Series C · Austin, Texas · founded 2016 · 58 employees$68Mraised▾
Pattern is a provider of multiple diagnostics platforms for infectious diseases. It provides digital culture technology that combines single-cell analysis with AI pattern recognition to bypass time-consuming culture steps. It provides solutions technology to fight against antibiotic resistance.
- Jul 2025Series C$44.2M
- Apr 2023Series C$28.7M
- Jul 2020Series B$9M
- Feb 2020Series A$6.8M
#2
Series B · Austin, Texas · founded 2020 · 2251 employees$9.8Mraised▾
Provider of self collecting COVID-19 testing center listing platform. Users can find a COVID-19 testing center in their locality, book a schedule for a test, and give the samples for testing. The test results can be collected by the users later.
- Oct 2025Series B$152.5M
- Sep 2021Series A$1M
- 2021Series A$8.8M
#3
Series B · Austin, Texas · founded 2017 · 27 employees$20Mraised▾
Developer of handheld PCR device for the detection of infectious disease. The device NUCLEIN uses standard real-time PCR, requires no technical expertise, battery-powered, results in one hour. This device can be used for covid diagnosis.
- Jul 2025Conventional Debt$19.1M
- Jan 2025Series B$9.4M
- Dec 2023Conventional Debt$8.8M
- Mar 2023Series B$4.2M
#4
Series A · Austin, Texas · founded 2015 · 13 employees$10.8Mraised▾
Engineering personalized human blood to optimize cognitive performance and reverse Alzheimer's disease. The company claimed that it has successfully patented key innate immune system mimetics. The company's Heterochronic Optimized Plasma Exchange (HOPE) for Alzheimer’s.
- Aug 2025Series A$20M
- Mar 2022Seed$10.8M
- Apr 2021Angel—
#5
Series A · Houston, Texas · founded 2019 · 4 employees$14.5Mraised▾
Developer of medicines for cancer, autoimmune, and infectious diseases. The company's lead antibody, ASY-77A, enhances antigen presentation by targeting the extracellular form of heat shock protein. Another candidate ASY-77A has produced complete regression of various cancer types including solid tumors such as breast and colon cancer, and blood-related cancers like multiple myeloma.
- Apr 2025Grant (prize money)$241.4K
- Apr 2022Grant (prize money)$246.5K
- Mar 2021Series A$14.5M
#6
Series A · Houston, Texas · founded 2004 · 9 employees$12Mraised▾
Developer of immunotherapies to treat cancer. The company's lead immunotherapy, MEM-288, is to treat patients with advanced cancers including lung, breast, pancreatic, and prostate cancers. Other candidates include MEM 40 to treat COVID-19.
- Nov 2024Series A$950K
- Jun 2023Series A$625K
- Dec 2021Series A$9.8M
- Jul 2020Seed$575K
#7
Seed · Euless, Texas · founded 2014 · 10 employees$2Mraised▾
Developing immunotherapies to prevent and treat life-threatening diseases. The company is focused on creating a platform of immunotherapies to address critical unmet needs in healthcare. Their innovative small molecules are designed to modulate the body's immune response, offering a balanced approach to fighting inflammation and infection. This approach aims to prevent tissue damage, promote cell growth, and overcome multi-drug resistance, providing effective solutions for ICU patients and others facing life-threatening conditions. Their therapies are designed to be accessible and affordable globally, with ongoing preclinical research and plans for human clinical trials. This is a biotech company focused on novel therapeutics and pharmaceutical solutions.
- Mar 2025Grant (prize money)$1.6M
- Apr 2024Grant (prize money)$895.4K
- May 2023Grant (prize money)$550.6K
- May 2022Grant (prize money)$2M
#8
Seed · Bryan, Texas · founded 2013 · 6 employees$4.2Mraised▾
Developing novel solutions for drug-resistant bacterial and fungal infections. The company is focused on combating drug resistance with innovative treatments for acute and chronic illnesses. Their pipeline includes solutions for antibiotic-resistant bacteria, such as MRSA, and fungal infections, including recurrent vulvovaginal candidiasis. They are developing first-in-class treatments to address the growing challenge of drug resistance in systemic bacterial and invasive fungal infections. The company seeks investors to support the development of their pharmaceutical products, offering potential solutions for neglected infectious diseases and contributing to the resurgence of antibiotic discovery. Their work aims to reduce mortality and morbidity associated with emerging antibiotic-resistant infections.
- Jul 2024Grant (prize money)$300K
- Apr 2024Seed—
- Aug 2020Grant (prize money)$233K
- Feb 2017Grant (prize money)$3.1M
#9
Public · Houston, Texas · founded 2013 · 97 employees$151.3Mraised▾
Developer of T-cell therapies to treat infectious diseases. The company has developed a platform for developing the Viralym-M allogenic lead candidate for the treatment of multiple viral diseases. The company focuses on restoring natural T-cell immunity against virus-associated diseases in immunocompromised patients.
- May 2019Series B$121.3M
- Oct 2018Series A$30M
- Aug 2017Grant (prize money)$9M
- Jun 2017Grant (prize money)$3M
#10
Series D · San Antonio, Texas · founded 2009 · 79 employees$94.4Mraised▾
Xenex provides disinfection robots for multiple healthcare purposes. It offers hospital sterilization robots that use strong, ultraviolet lights (termed patented Xenon Pulse or UV technology) to kill infection-causing microorganisms. Their patented room disinfection system reduces the bacterial load that is often associated with an increased risk for healthcare-associated infections (HAIs).
- Feb 2019Series D$6M
- Feb 2018Series D$40M
- Sep 2016Series C$3M
- Jan 2015Series C$25M
#11
Series C · Austin, Texas · founded 2003 · 27 employees$90Mraised▾
Provider of vaccine development and management devices for researchers. The company has developed real-time data management IoT devices called Nano Sense for vaccine development and clinical trials. The platform has solutions that work on safety, study global pandemic data, and assist with vaccine development. The system detects infectious diseases for the identification of pathogens.
- Mar 2021Series C$90M
#12
Public · Dallas, Texas · founded 2019 · 92 employees$27Mraised▾
Developer of vaccines for neurological disorders and infectious diseases. The lead candidate is UB-612 for Covid-19 is a multitope peptide-based vaccine. Other candidates include UB-311 and Tau for Alzheimer’s, UB-312 for Parkinson's, UB-313 for chronic migraine, and PCSK9 for hypercholesterolemia. The company has proprietary synthetic peptide immunogens that activate B- and T-cell arms of the immune system and combine multiple antigens into a single formulation to develop multitope vaccines.
- Mar 2021Series B$27M
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Infectious Diseases coverage by sub-theme.
Regulatory-risk over time falling
Funding & growth over time
funding flat · growth falling
How research on Diagnostics in Texas is moving
A read on the academic research around Diagnostics in Texas — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 402 papers.
- The University of Texas MD Anderson Cancer Center191
- The University of Texas Southwestern Medical Center52
- The University of Texas Medical Branch at Galveston30
- The University of Texas Health Science Center at Houston27
- Texas A&M University23
- Point of care1→13
- Point-of-care testing1→10
- Biomarker1→7
- Liquid biopsy11→14
- Transcriptome1→3
- Liquid biopsy11→48
- Biopsy3→19
- Lung cancer4→17
- Breast cancer2→12
- Circulating tumor cell4→13
- Biomarker1→8
- Liquid biopsy3→8
- Point of care4→7
- Biopsy2→4
- Disease3→4
Common questions
Riya reads income statements for fun. She covers the real money in a sector — revenue, growth, who actually earns — and never met a vague claim she didn't want a number for.